dc.contributor.author |
Chen, C.L. |
en_US |
dc.contributor.author |
Venketasubramanian, N. |
en_US |
dc.contributor.author |
Lee, C.F. |
en_US |
dc.contributor.author |
Wong, K.S. |
en_US |
dc.contributor.author |
Bousser, M.G. |
en_US |
dc.contributor.author |
CHIMES Study Investigators |
en_US |
dc.contributor.author |
de Silva, A. with 38 CHIMES Study Investigators |
en_US |
dc.date.accessioned |
2014-10-29T09:41:03Z |
|
dc.date.available |
2014-10-29T09:41:03Z |
|
dc.date.issued |
2013 |
en_US |
dc.identifier.citation |
Stroke. 2013; 44(12):3580-3.[Epub 2013 Oct 17.] |
en_US |
dc.identifier.issn |
0039-2499 (Print) |
en_US |
dc.identifier.issn |
1524-4628 (Electronic) |
en_US |
dc.identifier.other |
10.1161/STROKEAHA.113.003226 |
en |
dc.identifier.uri |
http://repository.kln.ac.lk/handle/123456789/2270 |
|
dc.description.abstract |
BACKGROUND AND PURPOSE: Early vascular events are an important cause of morbidity and mortality in the first 3 months after a stroke. We aimed to investigate the effects of MLC601 on the occurrence of early vascular events within 3 months of stroke onset. METHODS: Post hoc analysis was performed on data from subjects included in the CHInese Medicine Neuroaid Efficacy on Stroke recovery(CHIMES) study, a randomized, placebo-controlled, double-blinded trial that compared MLC601 with placebo in 1099 subjects with ischemic stroke of intermediate severity in the preceding 72 hours. Early vascular events were defined as a composite of recurrent stroke, acute coronary syndrome, and vascular death occurring within 3 months of stroke onset. RESULTS: The frequency of early vascular events during the 3-month follow-up was significantly less in the MLC601 group than in the placebo group (16 [2.9%] versus 31 events [5.6%]; risk difference=-2.7%; 95% confidence interval, -5.1% to -0.4%; P=0.025) without an increase in nonvascular deaths. Kaplan-Meier survival analysis showed a difference in the risk of vascular outcomes between the 2 groups as early as the first month after stroke (Log-rank P=0.024; hazard ratio, 0.51; 95% confidence interval, 0.28-0.93). CONCLUSIONS: Treatment with MLC601 was associated with reduced early vascular events among subjects in the CHIMES study. The mechanisms for this effect require further study. CLINICAL TRIAL REGISTRATION URL://www.clinicaltrials.gov. Unique identifier: NCT00554723. |
|
dc.publisher |
Lippincott Williams and Wilkins |
en_US |
dc.source.uri |
http://stroke.ahajournals.org/content/44/12/3580.long |
en |
dc.title |
Effects of MLC601 on early vascular events in patients after stroke: the CHIMES study |
en_US |
dc.type |
Article |
en_US |
dc.identifier.department |
Pharmacology |
en_US |
dc.creator.corporateauthor |
American Heart Association |
en_US |
dc.description.note |
Indexed in MEDLINE |
en_US |